Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity

European Cytokine Network

Volumn 12, Issue 3, 2001, Pages 445-452

  Robak, E ^a   Woniacka A ^a   Sysa Jedrzejowska A ^a   Stepien H ^a   Robak, T ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Angiogenesis; Basic fibroblast growth factor; Disease activity; Hepatocyte growth factor; Platelets; Systemic lupus erythematosus; Transforming growth factor ; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOKINE PRODUCTION; DISEASE ACTIVITY; FEMALE; HUMAN; IMMUNOPATHOGENESIS; MAJOR CLINICAL STUDY; MALE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; CYTOKINES; ENDOTHELIAL GROWTH FACTORS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HEPATOCYTE GROWTH FACTOR; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOKINES; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PLATELET COUNT; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034813356     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Clinical applications of research on angiogenesis
2. Angiogenesis in cancer, vascular, rheumatoid and other diseases
3. Vascular permeability factor/vascular endothelial growth factor: An important mediator of angiogenesis in malignancy and inflammation
4. Manipulating angiogenesis. From basic science to the bedside
5. Vascular endothelial growth factor (VEGF) and its effect on angiogenesis
6. Current status of antiangiogenic factors
7. Clinical significance of the determination of angiogenic factors
8. Elevated levels of angiogenic cytokines in the plasma of cancer patients
9. Vascular endothelial growth factor in patients with rheumatoid arthritis
10. Serum concentrations of basic fibroblast growth factor in collagen diseases
11. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma
12. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma
13. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients
14. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia
15. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma
16. Serum concentrations of vascular endothelial growth factor in collagen diseases
17. The 1982 revised criteria for the classification of systemic lupus erythematosus
18. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus
19. The tumor necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis
20. Tumor necrosis factor α (TNF-α), interleukin-6 and their soluble receptors (sTNF-α-R, p55 and sIL-6R) serum levels in systemic lupus erythematosus
21. Decreased production of TGF-beta by lymphocytes from patients with systemic lupus erythematosus
22. Increase excretion of urinary transforming growth factor beta in patients with focal glomerular sclerosis
23. Clinical features of SLE
24. Lupus anticoagulant and the skin. A long term follow-up study of SLE patients with special reference to histopathological findings
25. Angiogenic factors in multiple myeloma: Higher levels in bone marrow than in peripheral blood
26. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor
27. Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells
28. Interleukin-6 induces the expression of vascular endothelial growth factor
29. Angiogenesis inhibition: A review
30. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease
31. A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12
32. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: The role of angiogenic factors
33. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis
34. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10
35. Inhibition of angiogenesis by interleukin-4
36. Involvement of basic fibroblast growth factor in fibroblast - Stimulatory serum activity of a patient with systemic lupus erythematosus and multiple dermatofibromas
37. Thalidomide in dermatology. New indications for an old drug
38. Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus
39. Anti-angiogenic agents: Clinical trial design and therapies in development